Keywords: Astellas, EC905, LUTS, Urinary tract, EU, Vivus, Avanafil, Erectile dysfunction, ED, EMA
Astellas files for EU approval of EC905, EMA accepts avanafil filing
Article | 28 March 2012
The European subsidiary of Japanese drug major Astellas Pharma (Tokyo: 4503) has announced the submission of a Market Authorization Application for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
